Versican, biglycan, and decorin protein expression patterns in coronary arteries: Analysis of primary and restenotic lesions

Cardiovascular Pathology

Volumn 7, Issue 1, 1998, Pages 31-37

  Lin, Hong ^a   Kanda, Tsugiyasu ^b   Hoshino, Yoichi ^b   Takase, Shin Ichi ^c   Kobayashi, Isao ^a   Nagai, Ryozo ^b   McManus, Bruce M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GUNMA UNIVERSITY   (Japan)

^c Gunma Cardiovascular Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; DECORIN; PROTEOGLYCAN; VERSICAN;

ADULT; AGED; ARTICLE; ATHERECTOMY; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS;

EID: 0031963949     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(97)00057-4     Document Type: Article

References (37)

1. Vlietstra RE, Holmes DR Jr., Smith HCet al. Percutaneous transluminal coronary angioplasty. initial Mayo Clinic experience Mayo Clin Proc. 56:1981;287-293.
2. Holt GW, Gersh BJ, Holmes DR Jret al. Results of percutaneous transluminal coronary angioplasty for angina pectoris early after myocardial infarction. Am J Cardiol. 61:1988;1238-1242.
3. Meyer J, Merx W, Schmitz Het al. Percutaneous transluminal coronary angioplasty after intracoronary streptolysis of transmural myocardial infarction. Circulation. 71:1985;754-760.
4. Mabin TA, Holmes DR Jr., Smith HC Follow-up clinical results in patients undergoing percutaneous transluminal coronary angioplasty. Circulation. 71:1985;754-760.
5. Cowley MJ, Vetrovec GW, Wolfgang TC Efficacy of percutaneous transluminal coronary angioplasty. technique, patient selection, salutary results, limitations, and complications Am Heart J. 101:1981;272-280.
6. Kent KM, Bentivoglio LG, Block PCet al. Long-term efficacy of percutaneous transluminal coronary angioplasty (PTCA). report from the National Heart, Lung and Blood Institute PTCA Registry Am J Cardiol. 53:1984;27C-81C.
7. Meier B, King SB III, Gruentzig ARet al. Repeat angioplasty. J Am Coll Cardiol. 4:1984;463-466.
8. Holmes DR Jr., Vlietstra RE, Smith HCet al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA). a report from PTCA Registry of the NHLBI Am J Cardiol. 53:1984;77C-81C.
9. Meier B, King SB III, Gruentzig ARet al. Repeat coronary angioplasty. review of the literature Eur Heart J. 9(suppl C):1988;1-6.
10. Corcos T, David PR, Val PGet al. Failure of diltiazem to prevent stenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 109:1985;926-931.
11. Faxon DP, Sanborn TA, Haudenschild CC Mechanism of angioplasty and its relation to restenosis. Am J Cardiol. 60:1987;5B-9B.
12. Thornton MA, Gruentzig AR, Hollman Jet al. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty. a randomized study Circulation. 69:1984;721-727.
13. Grigg LE, Kay TWH, Valentine PAet al. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. J Am Coll Cardiol. 13:1989;665-672.
14. Garratt KN, Edwards WD, Kauffmann UPet al. Differential histopathology of primary atherosclerotic and restenotic lesions in coronary arteries and saphenous vein bypass grafts. analysis of tissue obtained from 73 patients by directional atherectomy J Am Coll Cardiol. 17:1991;442-448.
15. Block PC, Myler RH, Stertzer S, Fallon JT Morphology after transluminal angioplasty in human beings. N Engl J Med. 305:1981;382-385.
16. Lin H, Wilson JE, Roberts CRet al. Biglycan, decorin and versican in epicardial coronary arteries of human heart allografts. immunohistochemical evidence of particular patterns of deposition, distinctive from native atherosclerosis J Heart Lung Transplant. 15:1996;1233-1247.
17. Lin H, Ignatescu M, Wilson JEet al. Prominence of apolipoproteins B, (a) and E in the intimae of coronary arteries in transplanted human hearts. geographical relationship to vessel wall proteoglycans J Heart Lung Transplant. 15:1996;1223-1232.
18. Bianco P, Fischer LW, Young MFet al. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissue. J Biol Chem. 38:1990;1549-1563.
19. Fisher LW, Termine JD, Young MFet al. Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of spaces. J Biol Chem. 264:1989;4571-4576.
20. Jarvelainen HT, Kinsella MG, Wight TN, Sandell LJ Differential expression of small chondroitin/dermatan sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem. 266:1991;23274-23281.
21. Fisher LW, Hawkins GR, Tuross N, Termine JD Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem. 262:1987;9702-9708.
22. LeBaron RG, Zimmermann DR, Ruoslahti E Hyaluronate binding properties of versican. J Biol Chem. 267:1992;10003-10010.
23. Alavi MZ, Moore S Proteoglycan composition of rabbit arterial wall under conditions of experimentally induced atherosclerosis. Atherosclerosis. 63:1987;65-74.
24. Volker W, Schmit A, Oortmann W, Broszey T, Faber V, Buddecke E Mapping of proteoglycans in atherosclerotic lesions. Eur Heart J. II(Suppl):1990;29-40.
25. Radhakrishnamurthy B, Srinivasan S, Eberle K, Ruiz H, Dalferes ER Jr., Sharma C, Berenson GS Composition of proteoglycans synthesized by rabbit aortic explants in culture and the effect of experimental atherosclerosis. Biochem Biophys Acta. 964:1988;231-243.
26. Volker W, Schmit A, Buddecke E Cytochemical changes in a human arterial proteoglycan related to atherosclerosis. Atherosclerosis. 77:1989;117-130.
27. Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, Wight TN Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol. 144:1994;962-974.
28. Nikkai ST, Jarvelainen HT, Wight TN, Ferguson M, Clowes AW Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol. 144:1994;1348-1356.
29. Asundi VK, Dreher KL Molecular characterization of vascular smooth muscle decorin. deduced core protein structure and regulation of gene expression Eur J Cell Biol. 59:1992;314-321.
30. Yao LY, Moody C, Schonherr E, Wight TN, Sandell LJ Identification of proteoglycan versican in aorta and smooth muscle cells by DNA sequence analysis, in situ hybridization and immunohistochemistry. Matrix Biol. 14:1994;213-225.
31. 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem. 266:1991;17640-17647.
32. Rasmussen LM, Wolf YG, Ruoslahti E Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-β-activity. Am J Pathol. 147:1995;1041-1048.
33. Zimmerman DR, Rouslahti E Multiple domains of the large fibroblast proteoglycan, versican. EMBO J. 8:1989;2975-2981.
34. Handingham TE Proteoglycans. many forms and many functions FASEB J. 6:1992;861-870.
35. Hammond EH, Hansen JK, Spencer LSet al. Vascular rejection in cardiac transplantation. histological, immunopathologic and ultrastructural features Cardiovasc Pathol. 2:1993;21-34.
36. Angelini GD, Newby AC The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J. 10:1989;273-280.
37. Chow LH, Huh S, Jiang J, Zong R, Pickering JG Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Circulation. 94:1996;3079-3082.